Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Forte Biosciences, Inc. FBRX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
41/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$65.00
+107.8%

Forte Biosciences, Inc. (FBRX) is a Biotechnology company in the Healthcare sector, currently trading at $31.28. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is FBRX = $65 (+107.8% upside).

Valuation: FBRX trades at a trailing Price-to-Earnings (P/E) of -68 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 184.46.

Net income is $69M (loss), growing at -78.4%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $61M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 3.88 (strong liquidity). Debt-to-assets is 0%. Total assets: $83M.

Analyst outlook: 3 / 6 analysts rate FBRX as buy (50%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 38/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 64/100 (Pass), Income ?/100 (Fail).

$65.00
▲ 107.8% Upside
Average Price Target
The 12-month price target for Forte Biosciences, Inc. is $65.00.

FBRX SharesGrow Score Overview

49/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 38/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — FBRX

✗
VALUE Fail
38/100
FBRX trades at a trailing Price-to-Earnings (P/E) of -68 (S&P 500 average ~25). Forward PEG 184.46 — overvalued. Trailing PEG 11.19. Analyst consensus target is $65, implying +107.8% from the current price $31. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
FBRX: +0%/yr revenue is, -78.4%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet FBRX: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 3.88 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
FBRX: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 3 / 6 analysts rate FBRX as buy (50%). Analyst consensus target is $65 (+107.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range4.9-35.62
Volume213K
Avg Volume (30D)286.5K
Market Cap$434.34M
Beta (1Y)3.23
Share Statistics
EPS (TTM)-4.71
Shares Outstanding$147.18M
IPO Date2017-04-13
Employees14
CEOPaul A. Wagner
Financial Highlights & Ratios
EBITDA$-70.66M
Net Income$-69.38M
Operating Income$-70.66M
Total Cash$76.96M
Net Debt$-76.96M
Total Assets$82.78M
Price / Earnings (P/E)-6.6
Analyst Forecast
1Y Price Target$65.00
Target High$65.00
Target Low$65.00
Upside+107.8%
Rating ConsensusBuy
Analysts Covering6
Buy 50% Hold 50% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS34962G2084

Price Chart

Track all markets on TradingView
FBRX
Forte Biosciences, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
4.90 52WK RANGE 35.62

People Also View

CELC
CELC
Celcuity Inc.
$123.47
+2.17%
 ERAS
ERAS
Erasca, Inc.
$18.20
+1.96%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.70
+1.63%
 RZLT
RZLT
Rezolute, Inc.
$3.59
+1.13%
 CCCC
CCCC
C4 Therapeutics, Inc.
$2.89
+4.90%
 THRX
THRX
Theseus Pharmaceuticals, Inc.
$4.07
+0.12%
 DBTX
DBTX
Decibel Therapeutics, Inc.
$4.91
-0.81%
 HOWL
HOWL
Werewolf Therapeutics, Inc.
$0.92
+0.23%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message